234 related articles for article (PubMed ID: 33387566)
1. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
[TBL] [Abstract][Full Text] [Related]
2. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
Reynolds VL; Butler P; Abernathy MM; Aschenbrenner L; Best DD; Blank J; Crosby M; Custer L; Escobar PA; Kolaja K; Moggs J; Shuey D; Snyder C; Van Vleet T; Zhou J; Hart TK
Regul Toxicol Pharmacol; 2020 Nov; 117():104746. PubMed ID: 32911461
[TBL] [Abstract][Full Text] [Related]
4. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey.
Authier S; Brock WJ; Halpern W; Harris SN; Jones D; McGovern T; McGovern PD; Pugsley MK
Int J Toxicol; 2021 Dec; 40(6):487-505. PubMed ID: 34569357
[TBL] [Abstract][Full Text] [Related]
5. Drug development and nonclinical to clinical translational databases: past and current efforts.
Monticello TM
Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
[TBL] [Abstract][Full Text] [Related]
6. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
Sistare FD; DeGeorge JJ
Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
[TBL] [Abstract][Full Text] [Related]
7. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Forum Opinion Piece
Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
[TBL] [Abstract][Full Text] [Related]
9. Can lifecycle management safeguard innovation in the pharmaceutical industry?
Hering S; Loretz B; Friedli T; Lehr CM; Stieneker F
Drug Discov Today; 2018 Dec; 23(12):1962-1973. PubMed ID: 30342247
[TBL] [Abstract][Full Text] [Related]
10. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
[TBL] [Abstract][Full Text] [Related]
11. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
[TBL] [Abstract][Full Text] [Related]
12. Industry perspectives on biomarker qualification.
Lavezzari G; Womack AW
Clin Pharmacol Ther; 2016 Feb; 99(2):208-13. PubMed ID: 26378777
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical industry perspective on combination toxicity studies: Results from an intra-industry survey conducted by IQ DruSafe Leadership Group.
Birkebak J; Buckley LA; Dambach D; Musvasva E; Price K; Ralston S; Sacaan A
Regul Toxicol Pharmacol; 2019 Mar; 102():40-46. PubMed ID: 30576687
[TBL] [Abstract][Full Text] [Related]
14. Challenges and gaps in immunosafety evaluation of therapeutics: An IQ DruSafe survey.
Collinge M; Neff-LaFord H; Akella S; Fogal B; Fraser K; Jabbour J; Harper K; Maier CC; Malherbe L; Marshall N; Rao GK; Raman K; Skaggs H; Weber F; Fuller CL
Regul Toxicol Pharmacol; 2024 Jun; 150():105630. PubMed ID: 38642729
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of the European Federation of Pharmaceutical Industries and Associations Oligonucleotide Working Group Survey on Nonclinical Practices and Regulatory Expectations for Therapeutic Oligonucleotide Safety Assessment.
Tessier Y; Achanzar W; Mihalcik L; Amuzie C; Andersson P; Parry JD; Moggs J; Whiteley LO
Nucleic Acid Ther; 2021 Feb; 31(1):7-20. PubMed ID: 33054599
[TBL] [Abstract][Full Text] [Related]
16. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
17. Increasing the Reuse of Protein Non-Naïve Nonhuman Primates in Pharmaceutical Drug Discovery and Development: An Overview and Industry Position on the Challenges and Benefits.
Mattis C; Bratcher N; Burns M; Carosino C; de Zafra C; Fancher RM; Georgi K; Graff C; Hukkanen RR; Johnson C; Lao Y; Lange A; Lee D; Lepherd M; Maguire S; Malisauskas M; Manuel M; Miranda S; Reed L; Santos R; Sayers B; Shaw D; Shuster D
Int J Toxicol; 2022 Aug; 41(4):291-296. PubMed ID: 35656559
[TBL] [Abstract][Full Text] [Related]
18. A decade of drug metabolite safety testing: industry and regulatory shared learning.
Luffer-Atlas D; Atrakchi A
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):897-900. PubMed ID: 28797172
[No Abstract] [Full Text] [Related]
19. Drugs in control samples in nonclinical safety studies: a reconsideration.
Zimmer D
Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
[No Abstract] [Full Text] [Related]
20. The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry: Results of an IQ DruSafe Minipig Survey.
Colleton C; Brewster D; Chester A; Clarke DO; Heining P; Olaharski A; Graziano M
Toxicol Pathol; 2016 Apr; 44(3):458-66. PubMed ID: 27006130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
